OCUL · CIK 0001393434 · FY2025 live · 2025-12-31
OCULAR THERAPEUTIX, INC
View as
Model
Classic Z
FY2025
0.60
Zone
Distress
Prior
—
Market DD
—
1y PD
—
0.60
Z″ 3.49
Score 0.60 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.911.2 × = 1.09X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−1.431.4 × = −2.00X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.333.3 × = −1.10X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
4.260.6 × = 2.55X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.061 × = 0.06
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings.
Meridian Rank
41.09
0–100 · Classic Z family
Book standing
40
Year change
—
Market PD
—
O-score
44
Events on this name
Same published rows as Today.
No published events on this print.
Overview
rule-v1
OCULAR THERAPEUTIX, INC is on classic Z at 0.60 (distress) for FY2025, from an SEC 10-K. Book equity / liabilities is the line that sets the print; retained earnings / assets is the runner-up. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers. Buybacks can send retained earnings negative at otherwise healthy issuers. X4 is book equity.
Book screen Distress; market PD —. Market PD has not been priced on this name.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 62nd percentile in Healthcare.
Filing line items
Current assets
$782M
Total assets
$808M
Current liabilities
$51M
Total liabilities
$154M
Working capital
$731M
Retained earnings
−$1.2B
EBIT
−$270M
Total sales
$52M
Book equity
$654M
Accession 0001104659-26-010664. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as is a display overlay. X4 is book equity. Pulled 13 Sept 2026.